Global Scleroderma Market - 2024 - 2031

Scleroderma The Global Scleroderma Market size reached USD 2,169.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,468.3 million by 2031. The Scleroderma market is expected to exhibit a CAGR of 6.2% during the forecast period (2024-2031). As per the article published in Current Opinion in Rheumatology in 2021, global trends of scleroderma demonstrate a greater prevalence of scleroderma in European, North and South American patients compared with East Asian patients.

However, the greatest prevalence (47 in 100,000) was found among the indigenous peoples in Canada. Depending on the patient's age at presentation, there are phenotypic variations, with older individuals showing higher internal organ involvement and illness acceleration.

Scleroderma is a rare and chronic autoimmune condition that impacts the skin and additional organs of the body. The condition has featured the hardening and tightening of the skin and connective tissues, which can cause damage to internal organs and inadequate function. The growing number of scleroderma cases, market developments, new product approvals, increased research activities, funding and investments are among the factors influencing the global scleroderma market growth in the forecast period.

Market Dynamics

The Increasing Number of Product Approvals for Scleroderma Treatment is Expected to Drive the Global Scleroderma Market Growth.

The increasing number of product approval for scleroderma treatment is expected to drive the global scleroderma market growth in the forecast period. For instance, in February 2023, GSK plc a global biopharma company announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell inhibiting monoclonal antibody, for the potential treatment of systemic sclerosis. GSK plans to initiate a phase II/III trial of belimumab for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the first half of 2023.

Side Effects of Scleroderma Treatment Hamper the Global Scleroderma Market Growth.

Scleroderma therapeutics can cause side effects, depending on the specific medication or treatment used that is hampering the global scleroderma market growth. For instance, calcium channel blockers may cause headaches, constipation, palpitations (irregular or pounding heartbeat), drowsiness, flushing, dizziness, rash, nausea and swelling in the feet and lower legs. Immunosuppressant drugs suppress the immune system and reduce inflammation, but they can also increase the risk of infections, including serious fungal, viral or bacterial infections. Other potential side effects include liver toxicity, gastrointestinal issues and an increased risk of certain cancers.

Market Segment Analysis

The global scleroderma market is segmented based on treatment, disease type, end users, and region.

The Medication Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period.

Owing to the increasing product approvals the medication segment is estimated to dominate the global scleroderma market holding about 78.2% of the total scleroderma market by 2030. For instance, in October 2022, Michigan Medicine University clinicians acquired a USFDA license for tofacitinib. Tofacitinib, an immunosuppressant medication, has demonstrated optimistic outcomes in scleroderma patients. Investigators are also hopeful regarding the subsequent step of the investigation.

Market Geographical Share

North America Holds a Large Share of the Global Scleroderma Market.

North America occupied the highest global scleroderma market share of about 40.2% in 2022 which is expected to increase to 40.7%% by 2030. Owing to the increasing cases, government initiatives, various organizations spreading awareness about the disease, better reimbursement policies and the presence of key market players holding the majority of the global market.

For instance, according to the University of Michigan, it occurs in around 30 persons per million per year. There are an estimated 125,000 active cases in the US of the 2.5 million cases worldwide, accounting for around 5% of cases worldwide.

Scleroderma Market Companies

The major global players in the market include Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc., Actelion Pharmaceuticals, Inc.(Johnson&Johnson), Boehringer Ingelheim International GmbH(C.H. Boehringer Sohn Ag & Co. KG), Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc. and Allergan, Inc. (Abbvie) are among others.

Impact on Scleroderma Market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war has negatively impacted the market as because of the conflict-induced situations many research studies have been delayed directly impacting the global scleroderma market growth. For instance, according to a new article published in April 2022, Russia’s war in Ukraine has affected trials of Roche Holding AG’s latest testing of multiple sclerosis medication, as physicians rush to transfer patients who have become refugees to unexplored treatment bases.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.

Artificial Intelligence Impact Analysis

The perspective benefits offered by AI in scleroderma diagnosis and treatment are estimated to have a positive influence on the global scleroderma market. For instance, the open-source computer algorithm Vision Transformer (ViT) could catch anomalies on nail fold capillaroscopy (NFC) pictures, according to conclusions submitted at the annual meeting of the American College of Rheumatology ACR Convergence 2022.

Key Developments
• In September 2022, Sanofi a French multinational pharmaceutical and healthcare company, and Kadmon a biopharmaceutical corporation decided to perform a merger. After the buyout, Sanofi was expected to continue the development of a diffuse cutaneous state of systemic sclerosis (dcSSc) treatment, belumosudil (KD025).
• In January 2022, Paracrine, Inc., a San Diego company with a custom biologic therapy in late-stage clinical trials acquired the FDA clearance of its Investigational Device Exemption (IDE) to execute a pivotal trial titled Scleroderma Treatment with Celution Processed Adipose-Derived Regenerative Cells: A Randomized, Double-blind, Placebo-Controlled Study the ""STAR II Trial.""
• In July 2022, Aisa Pharma Inc., a clinical-stage pharma development corporation declared the favorable outcomes of its phase-2 study of Profervia, an oral calcium-channel antagonist indicated for the scleroderma treatment.

Why Purchase the Report?
• To visualize the global scleroderma market segmentation based on treatment, disease type, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of scleroderma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Scleroderma Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.